Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7954084 | 0.94 | ADRA1A (0.56) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7238400 | 0.94 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7246090 | 0.92 | ADRA1A (0.51) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7236524 | 0.91 | ADRA1A (0.54) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7239538 | 0.88 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7246549 | 0.87 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7239221 | 0.87 | ADRA1A (0.48) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7237999 | 0.86 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7242253 | 0.86 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7242493 | 0.86 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | ADRA1A 73/4885ADRA1D 77/4885ADRA1B 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.